Lung cancer in HIV-infected patients and the role of targeted therapy

Marco Ruiz; Robert A Ramirez

doi:10.12788/jcso.0152

Lung cancer in HIV-infected patients and the role of targeted therapy

J Community Support Oncol. 2015 Aug;13(8):282-7. doi: 10.12788/jcso.0152.

Authors

Marco Ruiz¹, Robert A Ramirez²

Affiliations

¹ Section of Hematology Oncology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA. mruiz@lsuhsc.edu.
² Section of Hematology Oncology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.

PMID: 26859668
DOI: 10.12788/jcso.0152

Abstract

Lung cancer is one of the most common malignancies in HIV-infected patients. Prevalence and mortality outcomes are higher in HIV-infected populations than in noninfected patients. There are several oral agents available for patients who harbor specific mutations, but little is known about mutations and affected pathways in HIV-infected patients with lung cancer. Recent trials have facilitated the inclusion of HIV-infected patients in clinical trials, but the population is remains underrepresented in oncology trials. Here, we review the literature on lung cancer in HIV-infected patients, and discuss common mutations in lung cancer and HIV-infected patients, the role of mutational analysis, and the potential role of targeted therapy in the treatment of lung cancer in HIV-infected populations.

Keywords: HIV; lung cancer; targeted therapy.